Bharat Biotech International Ltd., an unlisted vaccine maker, received regulatory approval to start human clinical trials for its experimental shot earlier this week and it already has India’s top medical research body expediting the process.
India has set an ambitious timeline for its first potential coronavirus vaccine — from human trials to general use in six weeks.
Bharat Biotech International Ltd., an unlisted vaccine maker, received regulatory approval to start human clinical trials for its experimental shot earlier this week and it already has India’s top medical research body expediting the process.
The under-development vaccine is “envisaged” to be rolled out “for public health use by Aug. 15 after completion of all clinical trials,” Indian Council of Medical Research, or ICMR, said in a July 2 letter to clinical trial sites, which was seen by Bloomberg News. It “is one of the top priority projects which is being monitored at the topmost level of the government.”
It has developed vaccines against polio, rotavirus, Japanese encephalitis and Zika, according to the statement.
Bharat Biotech “is working expeditiously to meet the target, however, final outcome will depend on the cooperation of all the clinical trial sites involved in the project,” the ICMR letter said.
